医学
诱导多能干细胞
临床试验
食品药品监督管理局
精密医学
药物开发
个性化医疗
重症监护医学
药品
风险分析(工程)
生物信息学
药理学
病理
胚胎干细胞
生物化学
化学
生物
基因
作者
Xuekun Wu,Kyle Swanson,Zehra Yıldırım,Wenqiang Liu,Ronglih Liao,Joseph C. Wu
标识
DOI:10.1093/eurheartj/ehae519
摘要
Abstract Cardiovascular diseases persist as a global health challenge that requires methodological innovation for effective drug development. Conventional pipelines relying on animal models suffer from high failure rates due to significant interspecies variation between humans and animal models. In response, the recently enacted Food and Drug Administration Modernization Act 2.0 encourages alternative approaches including induced pluripotent stem cells (iPSCs). Human iPSCs provide a patient-specific, precise, and screenable platform for drug testing, paving the way for cardiovascular precision medicine. This review discusses milestones in iPSC differentiation and their applications from disease modelling to drug discovery in cardiovascular medicine. It then explores challenges and emerging opportunities for the implementation of ‘clinical trials in-a-dish’. Concluding, this review proposes a framework for future clinical trial design with strategic incorporations of iPSC technology, microphysiological systems, clinical pan-omics, and artificial intelligence to improve success rates and advance cardiovascular healthcare.
科研通智能强力驱动
Strongly Powered by AbleSci AI